This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Quidel's CEO Presents At Canaccord Genuity 32nd Annual Growth Conference (Transcript)

Quidel Corp. (QDEL)

Canaccord Genuity 32nd Annual Growth Conference Transcript

August 14, 2012 10:00 AM ET

Executives

Doug Bryant - President and CEO

Randy Steward - Chief Financial Officer

Ruben Argueta - Investor Relations

Analysts

Jeff Frelick - Canaccord Genuity

Presentation

Jeff Frelick - Canaccord Genuity

Joining us today from Quidel we have Doug Bryant, we have Randy Steward, CFO; and Ruben Argueta, IR. So please join us across the room for breakout, immediately following the presentation.

As you know, Quidel is a leading point-of-care company. I think those again to a robust new product cycle that the company is embarking on. I’ll point you to book -- conference manuals for disclose statements.

And with that, I’d like to turn it over to Doug.

Doug Bryant

Thanks, Jeff, and good morning. We will be making forward-looking statements. This particular slide gets [denser] of how I think we present. Quidel is a company that’s very well-positioned and where it has become a fairly attractive diagnostic market space, in particular the area we focus in point-of-care and recently in molecular, those two areas are actually the fasted growing in that segment.

We have a fairly significant product pipeline that addresses a number of different market opportunities. We are known as an infectious disease company. So, clearly, we have products in development in that space, but we are also interested in the women’s health category and we have a number of products in development there.

Increasing commercial footprint, recently in U.S. we doubled our sales organization and those guys, at the moment are engaged in launching our newest product Sofia. I’ll talk more about that in a second. And finally, it is a company that has a healthy balance sheet, good revenues and very little debt.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,351.38 +293.03 1.82%
S&P 500 1,948.86 +35.01 1.83%
NASDAQ 4,749.9790 +113.8740 2.46%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs